WuXi Biologics’ 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site has successfully completed its first GMP production campaign. The manufacturing process execution was completed with zero deviations, while critical process parameters remained stable and yields reached...
Milliken Expands Innovation Capabilities with New Polymer Solutions Pilot Plant in Pune, India
Facility strengthens ability to accelerate development and scale advanced material solutions for global markets. PUNE, India, June 24, 2026 /PRNewswire/ -- Milliken & Company has opened a new state of the art pilot plant facility in Pune, India, further strengthening its polymer solutions business and advancing its ability to accelerate innovation for customers worldwide. The facility is designed...
UniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson’s Therapy
SHANGHAI, June 23, 2026 /PRNewswire/ -- UniXell Biotechnology Co., Ltd. ("UniXell") has secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for UX-DA003, its allogeneic induced pluripotent stem cell (iPSC)-derived therapy for Parkinson's disease. Paired with the prior IND approval from China's National Medical Products Administration (NMPA) on June 3, 2026, the candidate...
Finetech Debuts Fully Automatic Liquid Capsule Filling Machine at CPhI China 2026 in Shanghai
System delivers filling volume accuracy within ±2–3%, output of 15,600 capsules per hour, and in-line rejection rates below 0.2%, addressing critical dosing consistency requirements for pharmaceutical and nutraceutical manufacturers SHANGHAI, June 24, 2026 /PRNewswire/ -- Finetech Pharmaceutical Equipment exhibited its new fully automatic liquid capsule filling machine at CPhI & PMEC China 2026, held June 16–18 at the...
Cynosure Lutronic Spotlighted Structural Skin Tightening Innovation at IMCAS Asia 2026 in Bangkok
SINGAPORE, June 24, 2026 /PRNewswire/ -- Global medical aesthetics leader Cynosure Lutronic presented its latest non-invasive innovations at IMCAS Asia 2026 in Bangkok (19–21 June), featuring XERF™, a structural skin tightening treatment that focuses on comfort, safety, flexibility and no downtime. XERF reflects a shift in how skin ageing is addressed, moving beyond surface-level improvements to support firmness and...
Great Place To Work Reveals Southeast Asia’s Best Workplaces™ in Healthcare & Biopharma
SINGAPORE, June 24, 2026 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture, today announced the inaugural Southeast Asia's Best Workplaces™ in Healthcare & Biopharma 2026 list — a landmark recognition honouring 15 outstanding organizations that have set the benchmark for trust, care, innovation, and performance across one of...
Beyond Horizons, Forward Together | Kexing Biopharm Concludes Participation in CPHI & PMEC China 2026
SHENZHEN, China, June 24, 2026 /PRNewswire/ -- From June 16 to 18, the CPHI & PMEC China 2026 was held at the Shanghai New International Expo Center. Kexing Biopharm (688136.SH) showcased multiple self-developed innovative drug pipelines and over 30 products for international markets at the exhibition. The company was also invited...
Abbisko Therapeutics Deepens R&D Collaboration with Lilly
SHANGHAI, June 24, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic research collaboration and license agreement with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company. Under the agreement, the two companies will collaborate on the...
Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311
SHANGHAI, June 24, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) of China has cleared the clinical trial application for its innovative LILRB4/CD3 targeting T Cell Engager (TCE) bispecific antibody (R&D code: 6MW5311), for the treatment of hematologic malignancies, including acute myeloid...
Abu Dhabi Opens Strategic Life Sciences Corridor to California Through Biocom Partnership
ABU DHABI, UAE, June 24, 2026 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Biocom California, one of the world's largest life sciences associations representing more than 1,800 biotechnology, pharmaceutical and medical technology organisations, have announced a strategic partnership...
